Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie perorálního agonisty TLR8 selgantolimodu na HBsAg u účastníků s chronickou hepatitidou B a HIV

Bezpečnost, snášenlivost a dopad perorálního agonisty TLR8 Selgantolimodu na HBsAg u účastníků s chronickou hepatitidou B i HIV

The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.

The primary hypotheses of this study were:

  1. Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
  2. TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.

Přehled studie

Postavení

Ukončeno

Podmínky

Intervence / Léčba

Detailní popis

A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.

The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.

Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.

Typ studie

Intervenční

Zápis (Aktuální)

29

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Rio de Janeiro, Brazílie, 21040-360
        • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazílie, 91350-180
        • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
      • Lima, Peru, 04
        • Barranco CRS (Site ID: 11301)
    • California
      • San Diego, California, Spojené státy, 92103
        • UCSD Antiviral Research Center CRS (Site ID: 701)
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30308
        • The Ponce de Leon Center CRS (Site ID: 5802)
    • New York
      • New York, New York, Spojené státy, 10011
        • Weill Cornell Chelsea CRS (Site ID: 7804)
    • North Carolina
      • Greensboro, North Carolina, Spojené státy, 27401
        • Greensboro CRS (Site ID: 3203)
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
      • Cleveland, Ohio, Spojené státy, 44106
        • Case CRS (Site ID: 2501)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
        • Univ of Pittsburgh (Site ID: 1001)
      • Chiang Mai, Thajsko, 50200
        • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
    • Bangkok
      • Pathum Wan, Bangkok, Thajsko, 10330
        • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 70 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. HIV-1 infection
  2. Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
  3. CD4+ cell count ≥350 cells/mm3
  4. HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
  5. Positive or negative HBeAg
  6. Negative anti-HDV
  7. Current CHB infection
  8. HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
  9. Quantitative HBsAg >1000 IU/mL
  10. Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
  11. Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.

Exclusion Criteria:

  1. Receipt of treatment for HCV within 24 weeks prior to study entry
  2. Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
  3. Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
  4. History of HCC or cholangiocarcinoma
  5. Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
  6. History of solid organ transplantation
  7. Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
  8. History of uveitis or posterior synechiae
  9. Breastfeeding

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Arm A

Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks.

Two 1.5 mg tablets taken orally once a week

Ostatní jména:
  • SLGN
Komparátor placeba: Arm B

Participants received matching Placebo for Selgantolimod once weekly for 24 weeks.

Two matching placebo tablets taken orally once a week

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
Časové okno: From study treatment initiation through Week 24

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded.

Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome.

The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From study treatment initiation through Week 24
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
Časové okno: From study treatment initiation through Week 24

The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From study treatment initiation through Week 24
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
Časové okno: Week 24

The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Week 24

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
Časové okno: From Baseline (Entry) through Week 48

The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
Časové okno: Week 24

The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Week 24
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
Časové okno: From Baseline (Entry) through Week 48

The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Časové okno: From Baseline (Entry) through Week 48

Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Changes From Baseline in qHBsAg Levels
Časové okno: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48

The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry).

Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
Časové okno: From Baseline (Entry) through Week 48

HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Časové okno: From Baseline (Entry) through Week 48

Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Časové okno: From Baseline (Entry) through Week 48

Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Number of Participants With Plasma HIV RNA >50 Copies/mL
Časové okno: Weeks 2, 4, 24 and 48

The number of participants with detectable plasma HIV RNA >50 copies/mL will be reported.

Weeks 2, 4, 24 and 48
Number of Participants With Serum HBV DNA >50 IU/mL
Časové okno: Weeks 2, 4, 24 and 48

The number of participants with detectable serum HBV DNA >50 copies/mL will be reported.

Weeks 2, 4, 24 and 48

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. května 2023

Primární dokončení (Aktuální)

29. října 2025

Dokončení studie (Aktuální)

8. dubna 2026

Termíny zápisu do studia

První předloženo

9. září 2022

První předloženo, které splnilo kritéria kontroly kvality

20. září 2022

První zveřejněno (Aktuální)

22. září 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

17. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

26. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • A5394

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Individual participant data that underlie results in the publication, after deidentification

Časový rámec sdílení IPD

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

Kritéria přístupu pro sdílení IPD

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .